Literature DB >> 20414032

[Advanced gastric cancer in an elderly woman showing histopathologic CR after a course of S-1 and CDDP combination therapy].

Yoshio Kadokawa1, Kentaro Sonoda, Sanae Nakajima, Atsushi Kawabe, Hiroto Egawa.   

Abstract

An 80-year-old woman was diagnosed with advanced gastric cancer of T2N0H0P0M0, Stage IB. She was strongly advised to undergo surgery, but refused this option. Because the performance status (PS)was 1, combination chemotherapy with S1 100 mg/day (day 1-21) and CDDP 50 mg/m2 (day 8) was initiated. After one course of treatment was completed, she changed her mind and expressed the wish to undergo an operation for her disease, which led to proximal gastrectomy (double tract reconstruction) being performed. A histopathological examination revealed CR of the disease with no cancer cells. As the population grows older, the number of elderly patients with advanced gastric cancer will increase in the future. Therefore, S-1 and CDDP combination therapy may be a treatment of choice for gastric cancer with dose reduction according to patient status, if the elderly patient refuses a curative operation. It may well prove to be an effective treatment in the elderly provided the dosage and administration are appropriate.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20414032

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma.

Authors:  She-Gan Gao; Rui-Nuo Jia; Xiao-Shan Feng; Xuan-Hu Xie; Tan-You Shan; Li-Xian Pan; Na-Sha Song; Yu-Feng Wang; Kai-Li Ding; Li-Dong Wang
Journal:  World J Gastroenterol       Date:  2011-12-21       Impact factor: 5.742

2.  Effect of Ag-1031 on apoptosis in gastric cancer AGS cells and its effects on the PI3K/AKT/mTOR signaling pathway.

Authors:  Jianhua Dai; Danfeng Liu; Longjiang Chen; LiXia Sun
Journal:  Biotechnol Lett       Date:  2020-07-10       Impact factor: 2.461

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.